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Copper is an essential cofactor of cytochrome c oxidase (CcO), the
terminal enzyme of the mitochondrial respiratory chain. Inherited
loss-of-function mutations in several genes encoding proteins re-
quired for copper delivery to CcO result in diminished CcO activity
and severe pathologic conditions in affected infants. Copper sup-
plementation restores CcO function in patient cells with mutations
in two of these genes, COA6 and SCO2, suggesting a potential
therapeutic approach. However, direct copper supplementation
has not been therapeutically effective in human patients, under-
scoring the need to identify highly efficient copper transporting
pharmacological agents. By using a candidate-based approach, we
identified an investigational anticancer drug, elesclomol (ES), that
rescues respiratory defects of COA6-deficient yeast cells by in-
creasing mitochondrial copper content and restoring CcO activity.
ES also rescues respiratory defects in other yeast mutants of cop-
per metabolism, suggesting a broader applicability. Low nanomo-
lar concentrations of ES reinstate copper-containing subunits of
CcO in a zebrafish model of copper deficiency and in a series of
copper-deficient mammalian cells, including those derived from a
patient with SCO2 mutations. These findings reveal that ES can
restore intracellular copper homeostasis by mimicking the function
of missing transporters and chaperones of copper, and may have
potential in treating human disorders of copper metabolism.
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Copper is an essential micronutrient required for the assemblyand activity of cytochrome c oxidase (CcO), the terminal
enzyme of the mitochondrial respiratory chain that catalyzes the
reduction of molecular oxygen and drives mitochondrial energy
production (1, 2). CcO is a highly conserved, multimeric inner
mitochondrial membrane protein complex that has two copper-
containing subunits, Cox1 and Cox2, which together form its
catalytic core (2). Copper delivery to mitochondria and its in-
sertion into these copper-containing subunits is an intricate
process that requires multiple metallochaperones and ancillary
proteins (3). Failure to deliver copper to Cox1 and Cox2 disrupts
CcO assembly and results in a respiratory deficiency.
Cytosolic copper is delivered to the mitochondrial matrix via
the recently identified yeast protein Pic2 (4), where it is stored in
a ligand-bound form (5). This mitochondrial matrix copper pool
is the main source of copper ions that are inserted into the CcO
subunits in the mitochondrial intermembrane space (IMS) (6). Mo-
bilization of copper from the mitochondrial matrix to the IMS for its
delivery to copper sites in CcO subunits requires a number of evo-
lutionarily conserved proteins (3). The precise molecular functions of
these proteins have remained unsolved, except for the metal-
lochaperones Cox17, Sco1, Sco2, and Cox11, which have been shown
to transfer copper to CcO subunits in a bucket-brigade fashion (3).
Specifically, Cox17 receives copper from the mitochondrial matrix
and transfers it to Cox11 and Sco1/Sco2 (7), which then metallate
copper sites on Cox1 and Cox2, respectively (8, 9). Recently, two
other proteins, Coa6 and Cox19, have also been shown to be part of
this copper delivery pathway in the IMS (10–13).
In humans, inherited partial loss-of-function mutations in
SCO1, SCO2, and COA6 result in a CcO deficiency and are as-
sociated with hepatopathy, metabolic acidosis, cardiomyopathy,
and neurological defects in affected patients (14–16). Copper
supplementation rescues CcO deficiency in myoblasts from pa-
tients with mutations in SCO2 (17) and restores CcO activity in
COA6-deficient yeast and human patient cell lines (16, 18),
suggesting that efficient delivery of copper to mitochondria could
restore CcO activity by bypassing SCO2 and COA6 functions. In an
attempt to translate these observations in a clinical setting, s.c. in-
jections of copper histidine were administered to a patient with an
SCO2 mutation. Although copper supplementation improved the
patient’s hypertrophic cardiomyopathy, it did not improve other
clinical outcomes or survival (19). Thus, a more effective mecha-
nism for restoration of copper homeostasis will be required for
human therapeutic agents. The present study employed yeast
coa6Δ cells to identify compounds that can efficiently transport
copper across biological membranes and restore mitochondrial
respiratory chain function over a broad range of concentrations.
This approach identified elesclomol (ES), which was shown to
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reestablish subcellular copper homeostasis in copper-deficient
cells, highlighting its therapeutic potential for human diseases of
copper metabolism.
Results
A Targeted Search for Copper-Binding Agents Identifies ES as the
Most Potent Pharmacological Agent in Rescuing Respiratory Defects
of Yeast coa6Δ Cells. We tested a number of copper-binding
pharmacological agents (20) for their ability to rescue respiratory
deficient growth of coa6Δ cells. Among all of the compounds
tested, ES was unique in that it rescued respiratory growth at low
nanomolar concentrations without exhibiting overt toxicity over
a broad range of concentrations (SI Appendix, Fig. S1). ES res-
cued the respiratory growth of coa6Δ cells with an ED50 of
0.8 nM (SI Appendix, Fig. S2). ES-mediated growth rescue of
coa6Δ cells was also observed on solid growth medium contain-
ing a nonfermentable carbon source (Fig. 1A). Consistent with
the rescue of respiratory growth, ES supplementation restored
the oxygen consumption rate of coa6Δ cells to that of WT cells (Fig.
1B). To determine the biochemical basis for the observed respiratory
rescue of coa6Δ cells, we measured the assembly and activity of CcO-
containing mitochondrial respiratory chain supercomplexes by native
PAGE blotting and in-gel activity assay, respectively. ES supple-
mentation restored the abundance and activity of CcO-containing
supercomplexes to near-WT levels (Fig. 1 C–F). We next tested the
efficacy of ES in rescuing COA6 mutations observed in human pa-
tients by heterologous expression of yeast–human chimeric proteins
with patient mutations (W26C, W33R, and E54X) in yeast coa6Δ
cells (SI Appendix, Fig. S3A). Similar to coa6Δ cells, 10 nM ES or
10 μM copper supplementation rescued yeast coa6Δ cells expressing
patient mutations (SI Appendix, Fig. S3B). These results show that ES
is at least 1,000 times more potent than copper in rescuing the re-
spiratory growth defect of yeast coa6Δ cells.
A previous study has shown that ES scavenges copper from the
culture medium, enters the cell as an ES–copper complex, and
selectively accumulates in mitochondria, where it dissociates
from copper (21). Consistent with this concept, we observed an
almost complete rescue of mitochondrial copper levels in coa6Δ
cells supplemented with ES (Fig. 1G). ES supplementation also
moderately increased total cellular copper levels (Fig. 1H). To
further corroborate that ES increases mitochondrial copper
levels by actively transporting extracellular copper into the cells,
we decreased copper availability in the extracellular compart-
ment by cotreatment with ES and a known copper chelator,
bathocuproine disulfonate (BCS). As expected, BCS treatment
resulted in reduced respiratory growth of WT cells, which was
rescued by cotreatment with ES, suggesting that ES is also able
to overcome pharmacological copper deficiency by outcompeting
BCS (SI Appendix, Fig. S4A). Moreover, ES-mediated rescue of
coa6Δ was diminished in the presence of BCS (SI Appendix, Fig.
S4B). To determine whether ES is able to bypass a mitochondrial
copper transporter, Pic2, we performed ES supplementation in
pic2Δ and coa6Δpic2Δ cells. Although, under the conditions tested,
we did not observe a respiratory growth defect of pic2Δ cells, ES did
rescue coa6Δpic2Δ cells, suggesting that this compound can deliver
copper to the mitochondria independent of Pic2 function (SI Ap-
pendix, Fig. S4C). These results imply that ES-mediated rescue of
CcO function is driven by its ability to transport extracellular copper
to the mitochondria of coa6Δ cells.
ES Rescues Many Different Yeast Mutants with Impaired Copper
Metabolism. To test the specificity of ES-mediated rescue, we
shortlisted a number of yeast mutants of genes required for main-
taining cellular and mitochondrial copper homeostasis (1–3). We
prioritized genes based on their evolutionary conservation, presence
of pathogenic mutations in humans, and/or the existence of a re-
lated mouse phenotype (Fig. 2A). These yeast mutants showed a
pronounced respiratory-deficient growth phenotype in non-
fermentable media at 37 °C after 2 d of growth, which became
less evident after 4 d of growth (Fig. 2B). Most of the yeast
mutants were rescued with ES supplementation, albeit to dif-
ferent degrees, reflecting their distinct roles in cellular and mi-
tochondrial copper homeostasis (Fig. 2B). ES failed to rescue
sco1Δ cells, possibly because of the specific role of Sco1 as a
metallochaperone in inserting copper into the Cox2 subunit of
CcO (Fig. 2). We noticed that a higher concentration of ES is
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Fig. 1. ES supplementation rescues CcO assembly defects by restoring mitochondrial copper levels of coa6Δ cells. (A) Serially diluted WT and coa6Δ cells were seeded
on the indicated plates and incubated at 30 °C and 37 °C for 2 d (YPD) or 4 d (YPGE) before imaging. (B–F) WT, coa6Δ and coa6Δ cells supplemented with 20 nM ES
were cultured in YP galactose medium until early stationary growth phase followed by (B) oxygen consumption rate (OCR) measurement, (C) BN-PAGE/Western
analysis of mitochondrial respiratory chain supercomplexes containing Complex IV (CIV; also called CcO), (D) quantification of supercomplexes, (E) in-gel activity
staining for Complex IV, and (F) quantification of CcO activity, (G) mitochondrial copper levels, and (H) total cellular copper content. Error bars represent mean ± SD
(n = 3, two-tailed unpaired Student’s t test, *P < 0.05 and **P < 0.005). Data shown in A, C, and E are representative of at least three independent experiments.
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required to rescue ctr1Δ cells (SI Appendix, Fig. S5), which is
consistent with the severe reduction in copper levels in cells
lacking Ctr1 (22). Overall, these results suggest the broad ap-
plicability of ES in ameliorating defects of cellular and mito-
chondrial copper homeostasis.
ES Supplementation Rescues Levels of CcO Subunits in Mammalian
Cell Lines with Genetic Defects in Copper Metabolism. To expand on
our findings in yeast and to test the efficacy of ES in mammalian
cell culture models of copper deficiency, we constructed a Ctr1-KO
rat H9c2 cardiomyocyte cell line by CRISPR/Cas9. The Ctr1−/− cell
line was validated by demonstrating the loss of Ctr1 protein (Fig.
3A). As expected, the loss of Ctr1 led to an approximately fourfold
decrease in the levels of intracellular copper (Fig. 3B) and a con-
comitant reduction in the levels of the CcO subunit COX4 (Fig.
3C). Notably, Ctr1−/− cells exhibited elevated levels of CCS, the
copper chaperone of SOD1, which is known to increase during
copper deficiency (Fig. 3C). We used this validated Ctr1−/− cell line
to test the efficacy of ES in rescuing COX1, a copper-containing
subunit of CcO. The loss of Ctr1 resulted in reduced levels of
COX1 that were rescued by ES in a dose-dependent manner (Fig.
3D). Similarly, we also observed a dose-dependent rescue of COX1
levels in Ctr1−/−mouse embryonic fibroblasts (MEFs; Fig. 3E) (23).
However, we noticed ES toxicity at higher doses, which was
reflected in reduced COX1 levels in control MEFs (Fig. 3E).
Finally, we tested the efficacy of ES in rescuing CcO defects in
fibroblasts from a patient with SCO2mutations that were previously
shown to have a COX2 deficiency (17). Unlike copper supple-
mentation, ES treatment was able to partially rescue the steady-
state levels of COX2 in a dose- and time-dependent manner (Fig.
3F). Notably, ES toxicity occurs at a concentration 20× higher than
the dose that rescued COX2 levels (Fig. 3F and SI Appendix, Fig.
S6A). Consistent with the known anticarcinogenic activity of ES, we
observed much more pronounced toxicity in immortalized cell lines
(SI Appendix, Fig. S6A) compared with primary cultures of the same
cell type (SI Appendix, Fig. S6B). Together, these results suggest
that a low nanomolar concentration of ES is efficacious in rescuing
mitochondrial copper deficiency and restoring CcO levels in
mammalian cell lines with genetic defects in copper homeostasis.
ES Supplementation Rescues Copper-Deficiency Phenotypes in Zebrafish
Models.To determine whether ES can rescue phenotypes associated
with copper deficiency in an intact developing vertebrate animal
model, we utilized zebrafish embryos with a null mutation in the gene
encoding the plasma membrane copper importer Ctr1. We chose
zebrafish because of the ability to quickly monitor the pigmentation
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Fig. 2. ES can rescue the respiratory growth deficiency of yeast mutants of copper metabolism. (A) List of yeast genes and their human orthologs implicated
in cellular and mitochondrial copper metabolism and the clinical phenotypes associated with mutations in the human or murine genes. (B) Serially diluted
WT cells and the indicated mutants were spotted on YPD, YPGE, and YPGE supplemented with 10 nM of ES. The plates were incubated at 37 °C and allowed to
grow for 2 d (YPD) or 2 d and 4 d (YPGE) before imaging.
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defect that arises as a result of the copper requirement of tyrosinase,
an enzyme that catalyzes the critical step in melanin biosynthesis. WT
zebrafish embryos have a characteristic melanin pigmentation pattern
visible at 48 h post fertilization (hpf; Fig. 4A). To determine if ES can
rescue copper-deficiency phenotypes in zebrafish, we incubated
zebrafish embryos from heterozygous ctr1 crosses in 10 nM ES and
compared these vs. untreated embryos. We found that the expected
∼25% of untreated embryos from ctr1 heterozygous crosses lacked
melanin deposition (16 of 59; Fig. 4B), whereas all of the ES-treated
embryos from the same crosses were pigmented (49 of 49; Fig. 4C).
Similarly, we also observed rescue of the pigmentation defect at
100 nM ES, but the equivalent dose of copper failed to rescue this
defect (SI Appendix, Fig. S7). ctr1−/− mutants also exhibited a CcO
assembly defect that was likely a result of mitochondrial copper
deficiency. To determine whether ES can rescue the observed CcO
assembly defect, we grew clutches of embryos from heterozygous
ctr1 crosses in the presence of ES until 10 d post fertilization (dpf)
and measured levels of Cox1 in their mitochondrial extracts.
Compared with WT embryos, the ctr1−/−mutants exhibited a severe
reduction in Cox1 levels that was almost completely rescued by
treatment with ES (Fig. 4D).
To further establish the potential of ES to treat metabolic
diseases involving defective copper delivery to the mitochon-
drion, we tested the efficacy of ES in rescuing phenotypes
associated with coa6 knockdown in zebrafish embryos (18). First,
we determined the maximal tolerable dose of ES for zebrafish
embryos to be 100 nM (SI Appendix, Fig. S8A). Consistent with
the mechanism of action of ES, we observed that cosupple-
mentation of 100 nM ES with 100 nM of copper resulted in
100% lethality (SI Appendix, Fig. S8B). As shown previously (18),
zebrafish embryos injected with the zfcoa6 translation-blocking
morpholino exhibited pronounced morphological defects char-
acterized by pericardial edema, smaller heads and eyes, and
curved tails. The severity of these phenotypes was scored at four
different time points (24, 48, 72, and 96 hpf; SI Appendix, Fig.
S8C), and we observed rescue with 100 nM ES treatment as early
as 48 hpf (SI Appendix, Fig. S8D). Given that one of the most
striking features of Coa6 deficiency in this model is a pro-
nounced cardiac edema and a decreased heart rate (18), we next
determined whether ES treatment was able to rescue these
phenotypes. Indeed, 100 nM ES treatment prevented pericardial
edema and significantly increased the heart rate of Coa6-
knockdown zebrafish embryos at 72 and 96 hpf without alter-
ing the heart rate of control embryos (SI Appendix, Fig. S8 E and
F). These results demonstrate the efficacy of ES in rescuing
phenotypes associated with copper deficiency in intact living
vertebrate animals.
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Fig. 3. ES supplementation rescues the steady-state levels of copper-containing subunits of CcO in mammalian cell lines with genetic defects in copper
metabolism. (A) Immunoblot analysis of CTR1 in Ctr1+/+ and Ctr1−/− H9c2 cells. The arrowheads labeled “g” and “t” indicate the full-length glycosylated and
truncated forms of CTR1, respectively. (B) Total copper levels measured by ICP-MS in H9c2 cells. Data are presented as mean ± SD (n = 4, two-tailed unpaired
Student’s t test, **P < 0.001). (C) Immunoblot analysis of CCS, COX4, and GAPDH protein levels in Ctr1+/+ and Ctr1−/− H9c2 cells. GAPDH serves as a loading
control. (D) The Ctr1+/+ and Ctr1−/− H9c2 rat cardiomyocytes and (E) MEFs were cultured for 3 d with the indicated doses of ES followed by Western analysis of
COX1 protein levels. ATP5A is used as loading control. (F) Control (MCH46) and SCO2 patient cell lines were cultured for 3 or 6 d in the presence of the
indicated concentrations of ES or a copper–histidinate complex (Cu-His) in DMEMwith 10% FBS. The cellular COX2 levels were detected by SDS/PAGE/Western
blot analysis. β-Actin (ACTB) was used as a loading control.
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Discussion
Mitochondrial disorders of copper metabolism represent a sub-
set of inborn errors of mitochondrial energy metabolism for
which no therapy currently exists (24). A previous attempt to use
direct copper supplementation as a therapeutic approach was
unsuccessful (19), possibly because of stringent regulation of
systemic copper levels. Thus, there is an unmet need to develop
better copper delivery agents. With this goal in mind, we tested a
number of clinically used pharmacological agents on a yeast mi-
tochondrial disease model of COA6 deficiency and identified ES
as the most potent and best tolerated compound capable of re-
storing mitochondrial function. Subsequent experiments on other
yeast, murine, human, and zebrafish models established broad
applicability of ES in treating cellular and mitochondrial copper
deficiency. ES has undergone multiple human clinical trials, in
which it has exhibited a favorable toxicity profile (25, 26); thus, our
findings offer an exciting possibility of repurposing this anticancer
drug for the treatment of disorders of copper metabolism.
Pharmacological interventions that alter the subcellular con-
centration and distribution of metals in a targeted manner could
be of therapeutic benefit. For example, coadministration of
copper with disulfiram, a Food and Drug Administration-
approved drug, increased the activity of CcO in the brains of a
mouse model of Menkes disease, a genetic disorder character-
ized by systemic copper deficiency (27). Similarly, CuII-ATSM
has been shown to be efficacious in a transgenic mouse model of
amyotrophic lateral sclerosis (28). However, a comparative study
on the efficacy of these clinically used copper complexes in a
model of copper deficiency is lacking. Therefore, our study
identifying ES as the most potent pharmacological agent among
many of the clinically used copper chelators and ionophores
represents an important advance (SI Appendix, Fig. S1). The
physicochemical properties of ES, including its binding affinity,
its specificity for copper, and the redox potential of the ES–
copper complex, allow it to mimic a copper metallochaperone
(29). Higher affinity of ES for copper (II) compared with copper
(I) allows it to scavenge copper from the extracellular environ-
ment, where copper is more likely to exist in an oxidized state
(29). ES is unlikely to strip copper from intracellular proteins
because of the higher prevalence of copper in the reduced state
in the intracellular environment.
Although a previous study shows selective enrichment of the
ES–copper complex in the mitochondria (21), the rescue of yeast
atx1Δ and ccc2Δ, which have impaired copper homeostasis in the
Golgi compartment (1), suggests that ES is also able to deliver
copper to other subcellular compartments (Fig. 2). Indeed, the
rescue of the pigmentation defect observed in ctr1−/− zebrafish
caused by a defective secretory pathway enzyme also indicates
that ES could increase copper levels in other organelles (Fig. 4).
Finally, the rescue of the respiratory growth defect of ccs1Δ cells,
which are deficient in a metallochaperone for the cytosolic protein
Sod1, suggests that ES is also able to elevate cytosolic copper levels
(Fig. 2). Although the mechanism by which ES is able to deliver
copper to different subcellular compartments is not clear, it is
possible that some of the ES–copper complexes dissociate before
reaching mitochondria, thereby releasing free copper in the cyto-
plasm. Alternatively, excess mitochondrial copper may “leak” out
of the mitochondria and become available to other organelles.
Notwithstanding the mechanism, this interesting observation sug-
gests that ES could be efficacious in the treatment of more com-
mon disorders of copper deficiency, including Menkes disease.
Materials and Methods
Reagents.All copper-binding compoundswere purchased from Sigma-Aldrich
except for ES, which was purchased from Selleckchem. The yeast–human
hybrid (hyCOA6) gene construct was codon-optimized for yeast and syn-
thesized by using GeneArt Gene Synthesis (Life Technologies). The hybrid
gene hyCOA6 was cloned into pRS416 plasmid under the control of the yeast
Coa6 native promoter. COA6 patient mutations were introduced by site-
directed mutagenesis (QuikChange Lightning; Agilent Technologies) by us-
ing hyCOA6 as a template. All primers used in this study are listed in SI
Appendix, Fig. S9. All constructs were sequence-verified.
Yeast Strains and Culture Conditions. Saccharomyces cerevisiae strains used in
this study are listed in SI Appendix, Fig. S10. The authenticity of yeast strains
was confirmed by PCR as well as by replica plating on dropout plates. Yeast
cells were cultured in standard YP growth media including YPD (1% yeast
extract, 2% peptone, and 2% glucose), YPGal (2% galactose), YPGE (3%
glycerol + 1% ethanol), or synthetic media (SC glucose). For qualitative growth
measurement, 10-fold serial dilutions of overnight cultures were spotted on
YPD or YPGE plates and incubated at 30 °C and 37 °C for the indicated period.
Growth in liquid media was measured spectrophotometrically at 600 nm.
Mammalian Cell Culture. The human control MCH46 and SCO2 patient fi-
broblasts as well as the rat H9c2 control and Ctr1−/− cardiomyocytes were
cultured in high-glucose DMEM supplemented with 10% FBS (Sigma) and
1 mM sodium pyruvate (Life Technologies). The MEFs were cultured in
DMEM 10% FBS, 1 mM sodium pyruvate, 1× Minimum Essential Medium
nonessential amino acids (no. 11140; Life Technologies), 50 μg/mL uridine,
and 1× penicillin/streptamycin glutamine (no. 10378; Life Technologies). All
cell lines were cultured under 5% CO2 at 37 °C and were treated with in-
dicated concentrations of ES for 3–6 d before harvesting. Whole-cell protein
was extracted in lysis buffer (BP-115; Boston BioProducts) supplemented
with protease inhibitor mixture (Roche Diagnostics), and the protein con-
centrations were determined by the bicinchoninic acid assay (Thermo Fisher
Scientific).
Construction of a Ctr1-KO Rat H9c2 Cell Line. A CRISPR/Cas9-mediated Ctr1-KO rat
H9c2 cell line was generated by using lentiCRISPR v2 plasmid (no. 52961; Addgene).
A guide RNA sequence targeting exon 1 of the Ctr1 gene was identified by using
the online CRISPR design tool (crispor.tefor.net). Forward (5′ CACCGTGGT-
GATGTTGTCGTCCGTG 3′) and reverse (5′ AAACCACGGACGACAACATCACCAC 3′)
WT ctr1+/- x ctr1+/- ctr1+/- x ctr1+/- + ES
ctr1-/-WT ctr1-/-
+ ES
DCA B
Cox1
(57 kDa)
Atp5a
(60 kDa)
Fig. 4. ES supplementation rescues pigmentation and the Cox1 deficiency of ctr1-KO zebrafish. (A–C) Clutches of embryos from a WT zebrafish and from a
cross of a pair of ctr1+/− heterozygous zebrafish were imaged at 48 hpf following treatment with and without 10 nM ES. Arrows in B indicate homozygous
ctr1−/− embryos with a pigmentation defect. (D) Mitochondria were isolated from 10-dpf WT zebrafish and homozygous ctr1−/− zebrafish treated with and
without 10 nM ES. Mitochondrial samples were subjected to SDS/PAGE and immunoblotted using the Complex IV-specific antibody anti-Cox1. The mito-
chondrial protein Atp5a was used as a loading control.
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oligonucleotides were inserted into lentiCRISPR v2 plasmid. The transfection was
performed by using PolyJet (SignaGen Laboratories). Two days after transfection,
cells were plated on a 96-well plate containing 5 μg/mL puromycin selection
media. Each colony formed from single cells was isolated and established in
medium without puromycin. Disruption of the Ctr1 gene was confirmed by
genomic DNA sequencing.
Oxygen Consumption Measurement. For measurements of respiration rates,
cells were grown to late log phase in YPGal medium and then washed,
counted, and resuspended in fresh YPGal medium at 108 cells per milliliter.
The rate of oxygen consumption was then measured at 30 °C by using the
Oxytherm system (Hansatech). Cyanide-sensitive respiration was calculated
after the addition of 1 mM KCN, and the cyanide-insensitive respiration was
subtracted from the total respiration.
Immunoblotting and In-Gel Activities. SDS/PAGE and Blue Native PAGE (BN-
PAGE) were performed to separate denatured and native protein complexes,
respectively. For SDS/PAGE, mitochondrial lysate (20 μg) was separated on
NuPAGE 4–12% Bis-Tris gels (Life Technologies). For BN-PAGE, yeast mitochon-
dria were solubilized in buffer containing 1% digitonin (Life Technologies) by
incubating for 15 min at 4 °C. Clear supernatant was collected after a 20,000 × g
(30 min, 4 °C) spin, 50× G-250 sample additive was added, and 20 μg of protein
was loaded on a 3–12% native PAGE Bis-Tris gel (Life Technologies). Following
wet transfer, the membrane was probed with the following primary antibodies:
for yeast proteins, Cox2 1:50,000 (no. 110 271; Abcam) and porin 1:50,000 (110
326; Abcam); and for mammalian proteins, COX1 (no. 14705; Abcam), COX2 (no.
110258; Abcam), CTR1, COX4 (A21348; Thermo Fisher Scientific), CCS (FL-274;
Santa Cruz Biotechnology), GAPDH (G9545; Sigma), ATP5A (14748; Abcam),
and β-actin (A2228; Sigma). Western blots were developed by using Western
Lightning Plus-ECL (PerkinElmer). In-gel activity assay for mitochondrial re-
spiratory chain complex IV were performed as described previously (30).
Cellular and Mitochondrial Copper Measurements. Cellular and mitochondrial
copper levels were measured by using a PerkinElmer DRC II inductively
coupled plasma (ICP) mass spectrometer. Intact yeast cells and isolated mi-
tochondrial pellets were washed with 100 μM EDTA-containing water,
weighed, and digested with 40% nitric acid (TraceSELECT; Sigma) at 90 °C for
18 h. Samples were diluted in ultrapure metal-free water (TraceSELECT;
Sigma) and analyzed by ICP-MS. Copper standard solutions were prepared
by appropriate dilutions of commercially available mixed metal standards
(BDH Aristar Plus). Copper concentrations in mammalian cells were also
measured by ICP-MS.
Zebrafish Experiments. All zebrafish studies were approved by the Marine
Biological Laboratory Institutional Animal Care and Use Committee (no. 16–
38). WT AB strain and ctr1 heterozygous zebrafish were maintained and
crossed by using standard methods. Embryos were staged and raised in egg
water at 28.5 °C. For drug treatments, embryos from ctr1 heterozygous
crosses were incubated in 10 nM ES diluted in egg water beginning at 3 hpf.
For imaging live embryos at 48 hpf, representative embryos of each sample
were anesthetized in Tricaine, and imaging was performed on an Olympus
SZX12 stereomicroscope. For immunoblots, zebrafish mitochondrial protein
was prepared from 10-dpf larvae. Mitochondrial lysate was separated by
SDS/PAGE on 4–15% Mini-Protean TGX Gels (Bio-Rad) followed by Western
blot analysis using anti-Cox1 at 1:5,000 (anti-MTCO1; ab14705; Abcam) and
anti-Atp5a at 1:5,000 (ab110273; Abcam). The morpholino-based experi-
ments were performed as described previously (18).
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